China's in-vivo gene-editing pipeline reaches the clinic

Summary

China's in-vivo gene-editing pipeline reached the clinic in the first half of 2026. Huida Gene Therapeutics reported clinical data from a CRISPR RNA-editing therapy injected directly into the human brain to treat MECP2 duplication syndrome, billed in Chinese pharma press (医药魔方) as a world first for in-brain CRISPR delivery and the second CRISPR RNA-editing therapy globally to enter human testing. Separately, YolTech's YOLT-201 (for ATTR-PN/ATTR-CM) won clinical approval in March as China's first LNP-mediated in-vivo gene-editing drug to enter trials, and two paediatric personalised CRISPR therapies are advancing. Chinese outlets frame the moves as proof of domestic depth in gene-editing-plus-cell-therapy platforms, paralleling Intellia's Western filing.

By the numbers

• 1st, claimed world-first in-brain CRISPR RNA-editing injection (Huida, MECP2 duplication).
• 2nd, globally, of CRISPR RNA-editing therapies to enter human testing.
• Mar 2026, YolTech YOLT-201 clinical approval (ATTR-PN/CM).
• 1st, China's first LNP-mediated in-vivo gene-editing drug in trials.
• 2, paediatric personalised CRISPR therapies advancing in 2026.

Why it matters

China is fielding in-vivo gene edits roughly in step with US leaders, in a domestically-financed pipeline, while chip-export limits squeeze its AI-for-biology compute. In-brain CRISPR RNA editing is a frontier delivery claim that, if it holds, extends gene editing to the central nervous system, a target Western programs largely avoid.

What to watch

• Peer-reviewed publication and durability of Huida's in-brain data.
• YolTech YOLT-201 trial progress and any NMPA approval timeline.
• Whether Chinese in-vivo programs file outside China (US/EU).